Volume 1.19 | May 28

Prostate Cell News 1.19, May 28, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Mapping Tumor Heterogeneity With Quantum Dots
Using a mixture of four quantum dots linked to antibodies that can detect cancer-associated proteins, a research team from Emory University has developed a method for mapping the molecular heterogeneity of human prostate tumor biopsies obtained from cancer patients. [Press release from the National Cancer Institute discussing online prepublication in ACS Nano]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


Scientists Find Protein Spurs Spread of Prostate Cancer
Researchers have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis. [Press release from the Kimmel Cancer Center at Jefferson discussing online prepublication in Endocrine-Related Cancer]

Memorial Hermann Developing New Prostate Cancer Vaccine in Med Center
While the Food and Drug Administration has approved a vaccine that is being used right now to fight prostate cancer, a similar vaccine is being developed in the Texas Medical Center that may prove to be even more effective against the disease. [KHOU News]

Shrew Spit Tames Cancer Cells
Shrew spit is under investigation by Canadian scientists as a potential screening test and treatment for breast, prostate and ovarian cancers. [CBC News]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Reversal of Chemotherapy-Induced Leukopenia Using Granulocyte Macrophage Colony-Stimulating Factor Promotes Bone Metastasis That Can Be Blocked with Osteoclast Inhibitors
Researchers evaluated the ability of granulocyte macrophage colony-stimulating factor to promote bone metastases of breast cancer or prostate cancer in a mouse model of chemotherapy-induced leukopenia. [Cancer Res]

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Given discrepancies between preclinical and clinical observations of mammalian target of rapamycin (mTOR) inhibition in prostate cancer, researchers sought to determine the pharmacodynamic effects of the mTOR/TORC1 inhibitor rapamycin in men with intermediate- to high-risk prostate cancer undergoing radical prostatectomy. [Clin Cancer Res]

Human Prostatic Acid Phosphatase, an Authentic Tyrosine Phosphatase, Dephosphorylates ErbB-2 and Regulates Prostate Cancer Cell Growth
The data show that the phosphorylation level of ErbB-2 primarily at Tyr1221/2 correlates with the growth rate of both LNCaP and MDA PCa2b human prostate cancer cells. [J Biol Chem]

Molecular Mapping of Tumor Heterogeneity on Clinical Tissue Specimens with Multiplexed Quantum Dots
Here researchers report the use of multiplexed quantum dots and wavelength-resolved spectral imaging for molecular mapping of tumor heterogeneity on human prostate cancer tissue specimens. [ACS Nano]

Human Heterochromatin Protein 1 Isoform HP1(Beta) Enhances Androgen Receptor Activity and is Implicated in Prostate Cancer Growth
The findings indicate that HP1(beta) is involved in the proliferation of androgen receptor (AR)-expressing prostate cancer cells and progression to castration-resistant prostate cancer as an AR coactivator. [Endocr Relat Cancer]

Proteasomal Degradation Unleashes the Pro-Death Activity of Androgen Receptor
Here, researchers report that stress-induced proteasomal degradation of androgen receptor contributes to its pro-death activity. [Cell Res]

Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways is Synergistically Enhanced when Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumour Xenografts
Here researchers report greatly improved anti-tumour efficacy for both attenuated (dl1520) and highly potent (dl922-947) oncolytic mutants in combination with the current standard of care for late stage hormone-independent prostate cancers, mitoxantrone or docetaxel. [Hum Gene Ther]


A Phase III Randomized Trial of the Timing of Meloxicam With Iodine-125 Prostate Brachytherapy
Starting meloxicam 1 week prior to brachytherapy compared to starting immediately after the procedure did not reduce 1-month edema, improve International Prostate Symptom Scores at 1 or 3 months, or reduce the need for catheterization. [Int J Radiat Oncol Biol Phys]


Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Amgen Inc. announced that the European Commission has granted marketing authorization for Prolia(R) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. [Amgen Inc. Press Release]

Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer
Sanofi-aventis announced results from a Phase III trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy. [Sanofi-aventis Press Release]

Rensselaer Polytechnic Institute Wins $2.45 Million Grant To Support Stem Cell Research
Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been awarded a four-year $2.45 million grant from the New York Stem Cell Science Program of the Empire State Stem Cell Board. [Rensselaer Polytechnic Institute Press Release]

Maryland Stem Cell Research Commission Announces 42 Projects for Funding
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. [Maryland Stem Cell Research Commission Press Release]

HHMI Awards $79 Million for Science Education to Research Universities, Top Scientists
Howard Hughes Medical Institute (HHMI) announced new grants totaling $79 million that will help universities strengthen undergraduate and precollege science education nationwide. [Howard Hughes Medical Institute Press Release]


NIH Wants More (Not Total) Disclosure of Financial Conflicts
The federal government proposed an overhaul of regulations covering financial conflicts of interest in biomedical research. [National Institutes of Health, United States]

NIH Requests Comments on the Proposed Rule Applicable to Regulations on the Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors (NOT-OD-10-099) [National Institutes of Health, United States]

NIH Requests Comments on the Proposed Rule Applicable to Regulations on the Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors (NOT-OD-10-099) [National Institutes of Health, United States]

Notice of Format Clarification and Frequently Asked Questions (FAQs) for Funding Opportunity Announcement (FOA): RFA-HL-11-006, Next Generation Genetic Association Studies (U01) (NOT-HL-10-110) [National Institutes of Health, United States]

Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors; Proposed Rule (Docket Number: NIH-2010-0001) [National Institutes of Health, United States]

FDA Transparency Initiative: Draft Proposals for Public Comment Regarding Disclosure Policies of the U.S. Food and Drug Administration; Availability [Docket No. FDA-2009-N-0247] [Food and Drug Administration, United States]


American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Update Profile  |  Contact Us